Comparative risk of fracture in community-dwelling older adults initiating suvorexant versus Z-drugs: Results from LIFE study
- PMID: 36184747
- DOI: 10.1111/jgs.18068
Comparative risk of fracture in community-dwelling older adults initiating suvorexant versus Z-drugs: Results from LIFE study
Abstract
Background: An increased risk of fracture has been reported in older adults taking hypnotics. However, few studies have reported the comparative safety of hypnotics with different mechanisms of action. We examined the risk of fracture in older adults initiating suvorexant compared to those initiating Z-drugs.
Methods: We conducted a retrospective cohort study using a claims database within a longevity improvement and fair evidence (LIFE) study in Japan (1.5 million beneficiaries). People aged ≥65 years were included in this study. Exposure was defined as the initiation of either suvorexant or Z-drugs (eszopiclone, zolpidem, or zopiclone). The evaluated outcomes were hip fracture and all-cause fracture requiring hospitalization. We used inverse probability of treatment weights to adjust for confounding and followed the incidence of the outcome for three different periods: 30, 90, and 365 days. Cox proportional hazards models were fitted to the weighted population to estimate hazard ratios (HRs). Sensitivity analyses were performed with narrowed outcome definitions and inverse probability of censoring weights.
Results: We identified 16,148 suvorexant new users and 54,327 Z-drugs new users. During the 30-day follow-up, 21 (16.6 events per 1000 person-years) and 53 hip fractures (12.2 events per 1000 person-years) were identified among suvorexant and Z-drugs new users, respectively (HR: 1.01, 95% confidence interval [CI]: 0.58-1.76). The analysis for all-cause fracture showed an HR of 1.03 (95% CI: 0.78-1.36). Extended follow-up (90 and 365 days) showed similar results for both outcomes. Sensitivity analyses showed consistent results except for an increased risk of all-cause fracture requiring surgery (HR: 1.41, 95% CI: 0.87-2.29) during the 30-day follow-up.
Conclusions: This is the first study to show that suvorexant has a generally comparable risk of fracture as compared to Z-drugs. Further research is needed to investigate the potential short-term increased risk of all-cause fracture requiring surgery among suvorexant initiators.
Keywords: comparative safety; fracture; hypnotics; older adults; real-world data.
© 2022 The American Geriatrics Society.
Similar articles
-
Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study.PLoS One. 2023 Apr 24;18(4):e0284726. doi: 10.1371/journal.pone.0284726. eCollection 2023. PLoS One. 2023. PMID: 37093840 Free PMC article.
-
Association between the Use of Suvorexant and Hip Fracture in Older Adults in Japan Using a Nationwide Administrative Claims Database: A Matched Case-Control Study.Drugs Aging. 2023 May;40(5):439-447. doi: 10.1007/s40266-023-01033-5. Epub 2023 Apr 30. Drugs Aging. 2023. PMID: 37121956
-
Retrospective population cohort study on hip fracture risk associated with zolpidem medication.Sleep. 2014 Apr 1;37(4):673-9. doi: 10.5665/sleep.3566. Sleep. 2014. PMID: 24899758 Free PMC article.
-
Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis.PLoS One. 2017 Apr 27;12(4):e0174730. doi: 10.1371/journal.pone.0174730. eCollection 2017. PLoS One. 2017. PMID: 28448593 Free PMC article. Review.
-
Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis.JAMA. 2017 Dec 26;318(24):2466-2482. doi: 10.1001/jama.2017.19344. JAMA. 2017. PMID: 29279934 Free PMC article. Review.
Cited by
-
Orexin antagonists for insomnia.Can Fam Physician. 2024 Mar;70(3):183-184. doi: 10.46747/cfp.7003183. Can Fam Physician. 2024. PMID: 38499379 Free PMC article. No abstract available.
-
Association between the type of hypnotic drug and in-hospital fractures in older patients with neurocognitive disorders: A case-control study using a nationwide database.Geriatr Gerontol Int. 2023 Jul;23(7):500-505. doi: 10.1111/ggi.14600. Epub 2023 May 22. Geriatr Gerontol Int. 2023. PMID: 37218390 Free PMC article.
-
Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study.PLoS One. 2023 Apr 24;18(4):e0284726. doi: 10.1371/journal.pone.0284726. eCollection 2023. PLoS One. 2023. PMID: 37093840 Free PMC article.
References
REFERENCES
-
- Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97-111. doi:10.1053/smrv.2002.0186
-
- Morin CM, Leblanc M, Daley M, Gregoire J, Merette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123-130. doi:10.1016/j.sleep.2005.08.008
-
- Morin CM, Benca R. Chronic insomnia. Lancet. 2012;379(9821):1129-1141. doi:10.1016/S0140-6736(11)60750-2
-
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. doi:10.5664/jcsm.6470
-
- Xing D, Ma XL, Ma JX, Wang J, Yang Y, Chen Y. Association between use of benzodiazepines and risk of fractures: a meta-analysis. Osteoporos Int. 2014;25(1):105-120. doi:10.1007/s00198-013-2446-y
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
